This statistic depicts the biggest potential biotech and conventional pharmaceutical product launches globally in 2025 and their projected revenues for 2030, as of December 2024. Vertex' Vanza Triple, a cystic fibrosis treatment, is expected to garner some 8.3 billion U.S. dollars in 2030.

The big data pharmaceutical advertising market is segmented into four major product segments: software, services, training, and consulting. The software segment is the largest segment of the market, followed by the services segment. The software segment is expected to continue to dominate the market during the forecast period. Recent developments include: Bright Bytes is a platform dealing in data management that was acquired by Microsoft in February 2019. the agenda behind this acquiring was to initiate the collection, integration, as well as, report of information across various online platforms related to both the applications and services, for the target audience. , To increase its global footprint, IBM announced and launched IBM Cloud Multizone Region (MZR) in August 2019. This launch is expected to help the clients in adopting critical workloads prevalent in a hybrid cloud environment. , The big data pharmaceutical advertising market Research shares a brief analysis on the segmentation, drivers leading to the adoption of technology, and the opportunities in the highly competitive industry. It shares a detailed study on strategic analysis, market structure, market growth, competitive analysis, joint ventures, strategic alliance, recent developments new product developments, research and development, and merger and acquisition in the field of study. The report also briefs about the regions where the market is studied i.e. North America, Europe, Asia-Pacific, Middle East, and the Rest of the World (ROW).. Key drivers for this market are: Increasing adoption of big data analytics by pharmaceutical companies. Growing demand for personalized marketing.. Potential restraints include: Lack of expertise in big data analytics. Data privacy concerns.. Notable trends are: Use of artificial intelligence (AI) and machine learning (ML). Development of new data management and analysis tools..

Paclitaxel Drug Market Outlook

The global Paclitaxel Drug market size was valued at approximately USD 8.5 billion in 2023 and is projected to reach USD 14.7 billion by 2032, growing at a CAGR of 6.0% during the forecast period. The steady growth of this market can be attributed to several pivotal factors, including the increasing prevalence of cancer worldwide, advancements in drug delivery mechanisms, and growing awareness among healthcare providers and patients about the benefits of Paclitaxel in cancer treatment. The rising investment in cancer research and development also plays a significant role in propelling market growth.

A major growth driver for the Paclitaxel Drug market is the alarming increase in cancer incidence rates globally. Cancer remains one of the leading causes of mortality, and with improved diagnostic techniques, more cases are being identified at earlier stages. This directly boosts the demand for effective chemotherapy agents like Paclitaxel. Additionally, the aging global population, which is more susceptible to various forms of cancer, further accelerates the need for robust cancer therapies. As awareness about early cancer detection and treatment rises, the demand for Paclitaxel is expected to follow suit, ensuring sustained market growth.

Another critical factor contributing to the market's growth is the continuous innovation in drug formulation and delivery systems. For instance, the development of albumin-bound Paclitaxel has enhanced the drugÂ’s efficacy and reduced its side effects, making it a preferred choice among oncologists. Such innovations not only make the treatment more tolerable for patients but also expand the potential applications of Paclitaxel to treat a wider variety of cancers. Moreover, the integration of Paclitaxel with nanotechnology and targeted drug delivery systems promises to further enhance its therapeutic potential and market penetration.

Significant investments in cancer research and development also fuel the Paclitaxel Drug marketÂ’s expansion. Both governmental and private sectors are increasingly allocating funds to develop new and improved cancer therapies, including Paclitaxel-based treatments. This influx of investment facilitates extensive clinical trials, encourages pharmaceutical advancements, and supports the launch of new Paclitaxel formulations. Additionally, emerging economies are increasingly participating in the global cancer research arena, broadening the marketÂ’s geographical footprint and contributing to its growth dynamics.

The introduction of Docetaxel Trihydrate API into the pharmaceutical landscape has marked a significant advancement in cancer treatment options. As a critical component in the formulation of chemotherapy drugs, Docetaxel Trihydrate API offers enhanced solubility and stability, making it a preferred choice for drug manufacturers. Its role in improving the pharmacokinetic profile of cancer therapies has been pivotal, allowing for more effective drug delivery and absorption in patients. This innovation aligns with the ongoing efforts to refine chemotherapy agents, ensuring that they are not only effective but also minimize adverse effects on patients. The development of such APIs is crucial in the quest to provide more targeted and efficient cancer treatments, ultimately contributing to better patient outcomes and expanding the therapeutic arsenal available to oncologists.

Product Type Analysis

The Paclitaxel Drug market is segmented by product type into Albumin-bound Paclitaxel, Synthetic Paclitaxel, and Natural Paclitaxel. Albumin-bound Paclitaxel, also known as nab-paclitaxel, has gained considerable attention due to its improved delivery mechanism. By binding the drug to albumin, it enhances solubility and reduces the need for harmful solvents, thereby minimizing adverse reactions. This formulation has shown increased efficacy in treating metastatic breast cancer and non-small cell lung cancer, leading to its widespread adoption and contributing significantly to market revenue.

Synthetic Paclitaxel represents another crucial segment, offering a more consistent and scalable production process compared to its natural counterpart. The synthetic version has been pivotal in addressing the supply constraints associated with the extraction of natural Paclitaxel from the Pacific yew tree. This segment is gaining traction as it ensures a steady supply for burgeoning demand and supports large-scale manufacturing. Moreover, synthetic

According to Cognitive Market Research, the global Pharma Track and Trace Solutions market size is USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of 19.20% from 2024 to 2031.

North America held the major market of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 16.4% from 2024 to 2031.
Europe accounted for a share of over 30% of the global market size of USD XX million.
Asia Pacific held a market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 20.2% from 2024 to 2031.
Latin America's market will have more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 17.6% from 2024 to 2031.
Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 17.9% from 2024 to 2031.

Key driver of the Pharma Track and Trace Solutions Market

Rising Deployment of Track and Trace Solutions to Provide Viable Market Output

The pharma track and trace solutions market is witnessing a surge in deployment due to stringent regulations, such as serialization mandates, to curb counterfeit drugs and ensure patient safety. These solutions enable pharmaceutical companies to monitor and trace the whole lifecycle of a product, from manufacturing to distribution. With the rising demand for authenticity and regulatory compliance, the adoption of track-and-trace solutions is escalating, driving market growth and enhancing supply chain visibility and integrity.

For instance, in October 2022, Zebra Technologies Corporation introduced a new extended solution, PartnerConnect, for its partners utilizing RFID and Real-time Location Systems (RTLS). The latest launch delivers businesses a competitive edge by actively tracking and empowering them in the next decision-making in real-time.

(Source:https://www.logisticsit.com/articles/2022/10/20/zebra-introduces-new-partnerconnect-location-and-tracking-specialisation-for-channel-partners )

Rising Emphasis by Manufacturers on Safeguard to Propel Market Growth

In the pharma track and trace solutions market, manufacturers are increasingly prioritizing safeguards to ensure product authenticity and safety. This emphasis stems from regulatory requirements, consumer demand for transparency, and the rising incidence of counterfeit drugs. Manufacturers are implementing comprehensive track and trace solutions utilizing technologies like RFID and barcoding to monitor the whole supply chain, enabling real-time visibility and traceability to enhance drug safety and compliance.

For instance, In May 2022, OPTEL GROUP presented OPTCHAIN, a collection of modular intelligent supply chain solutions developed to facilitate the seamless capture and digitization of Critical Tracking Events and Key Data Elements throughout the whole supply chain in the food and beverage industry.

(Source: https://www.optelgroup.com/en/news/optel-group-launches-optchain-a-suite-of-intelligent-supply-chain-solutions-for-the-food-beverage-industry/ )

Restraint of the Pharma Track and Trace Solutions Market

High Cost of Implementation to Restrict Market Growth

In the pharma track and trace solutions market, the high cost of implementation serves as a significant restraint. Implementing track and trace solutions requires substantial investment in infrastructure, technology, and personnel training. This cost can be prohibitive for smaller pharmaceutical companies or those operating in regions with budget constraints, limiting their ability to adopt these solutions. Consequently, despite the benefits of enhanced security and compliance, cost barriers impede widespread adoption and market expansion in certain segments and regions.

Impact of COVID-19 on the Pharma Track and Trace Solutions Market

The COVID-19 pandemic has significantly impacted the pharma track and trace solutions market by highlighting the urgent need for robust supply chain visibility and product authentication. With heightened concerns about counterfeit drugs and the rapid distribution of vaccines and medications, pharmaceutical companies are increasingly investing in track-and-trace solu...

Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a natural process known as remodeling, some of the bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of new bone. Consequently, bones become more porous and fragile, leading to weakness of the skeleton and an increased risk of hip, spine, and wrist fractures. Osteoporosis is often referred to as a “silent” disease, because the loss of bone occurs progressively and often there are no symptoms until the first fracture occurs.
Despite being a market currently monopolized by generics, osteoporosis is expected to undergo substantial change between 2017 and 2027. Clear changes are already being seen with the recent launch of Radius Health’s Tymlos (abaloparatide) in the US in 2017. Anabolic agents are likely to further revolutionize the market with the arrival of a novel sclerostin inhibitor, Evenity (romosozumab), and teriparatide biosimilars. This diversification of the anabolic offering will increase competition in this space, driving down high price tags and potentially bolstering the use of these therapies up the treatment paradigm. The launch of Evenity will keep Amgen a key player in the osteoporosis market as they lose patent protection of current market leading therapy, Prolia (denosumab). The arrival of new anabolic agents and the loss of patent protection for key branded therapies will shape the osteoporosis market over the forecast period. However, poor diagnosis rates, badly perceived drug side effects, and low compliance rates will continue to prove major barriers to growth over the next 10 years.
Key Questions Answered
• What are the key osteoporosis treatments in 2017?
• When will the late stage pipeline products launch, and how will it affect drug sales and the overall osteoporosis market in the 7MM?
• Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies? Read More

As per Cognitive Market Research's latest published report, the Global Tablet Press Machine market size was $1,150.81 Million in 2024 and it is forecasted to reach $1628.98 Million by 2031. Tablet Press Machine Industry's Compound Annual Growth Rate will be 5.09% from 2024 to 2031.

The demand for tablet press machines is rising due to the growing demand for tablet press machines in the pharmaceutical industry.
The commercial category held the highest tablet press machine market revenue share in 2023.
The pharmaceutical category held the highest tablet press machine market revenue share in 2023.
North American will continue to lead, whereas the European tablet press machine market will experience the strongest growth until 2030.

Market Dynamics of the Tablet Press Machine Market

Driving Factor for the Tablet Press Machine

Technological Advancement by Key Players to Provide Viable Market Output

Key players in the tablet press machine market, such as Fette Compacting, IMA, and KORSCH, have driven technological progress. These innovations include improved automation, precision dosing, and real-time monitoring, enhancing tablet production efficiency and quality control. Integration of IoT and data analytics has allowed predictive maintenance, decreasing downtime. Moreover, eco-friendly techniques and materials are becoming noticeable, aligning with sustainability goals. These advancements ensure that the tablet press machine market continues to grow, meeting the demands of the pharmaceutical and nutraceutical industries effectively drives the market growth.

For instance, in July 2020, Korsch introduced a tablet press specifically developed for technical and chemical products with large formats, deeper filling depths, and higher compression forces. The XT 600 HD double rotary tablet press combines key facets of the company’s proven technology in a cost-effective platform.

(Source-www.powderbulksolids.com/pharmaceutical-medical-products/korsch-launch-new-double-rotary-tablet-press)

Expansion in the Pharmaceutical Industry to Propel Market Growthhttps://www.cognitivemarketresearch.com/articles/expansion-in-the-pharmaceutical-industry-will-propel-the-growth-of-tablet-press-machine-market

The robust expansion of the pharmaceutical industry serves as a significant catalyst for the tablet press machine market. As the demand for pharmaceutical products, particularly tablets, continues to surge, there is an increasing need for advanced tablet press machines to meet production requirements efficiently. This growth in pharmaceutical manufacturing fuels the demand for innovative and high-performance tablet press machines, ensuring that the Tablet Press Machine Market remains a pivotal player in supporting the pharmaceutical sector's expansion and technological advancements drives the market growth.

For instance, in March 2021, in the form of its F30i, Fette Compacting launched the second tablet press of its recent i Series. The high-performance dual rotary press is optimized for two-layer tablets. The new machine is designed for the production of large batches and enables an output of up to 1.6 million tablets per hour.

(Source-www.fette-compacting.com/en/newsroom/news-detail/f30i-double-rotary-press-the-next-generation)

Market Restraint of Tablet Press Machine

High Initial Cost to Hinder Market Growth

The tablet press machine market faces a significant restraint in the form of high initial costs. Acquiring and implementing advanced tablet press machines demands substantial upfront investments, often posing a challenge for smaller pharmaceutical manufacturers and new entrants. These elevated expenses can hinder market entry and limit the adoption of state-of-the-art technology, potentially creating disparities in production capabilities across the industry. Nonetheless, financial assistance options and leasing arrangements can provide some relief, easing the burden of these initial costs and encouraging broader market participation.

Impact of COVID–19 on the Tablet Press Machine Market

The tablet press machine market experienced a notable impact from the COVID-19 pandemic. Initially, disruptions in the supply chain and workforce limitations slowed production. However, as the pandemic continued, the demand for pharmaceuticals and vitamins surged, boosting the market's growth. This necessitated the...

The global lactose powder market is poised to witness significant growth over the forecast period, reaching a market size of XX million by 2033, expanding at a CAGR of XXX% from 2025 to 2033. This growth is attributed to various factors, including increasing demand for lactose in various food and beverage applications, rising health consciousness, and growing consumption of sports and dietary supplements. Key market segments include grade (food grade and pharmaceutical grade) and application (food & beverages, pharmaceuticals, and sports and dietary supplements). Geographically, North America, Europe, Asia Pacific, Latin America, and MEA constitute the major regional markets for lactose powder. Leading companies in the market include Lactalis Ingredients, FrieslandCampina Ingredients, Star Food Industries, and Lactose India Limited. Recent developments include: In October 2023, Lactalis Ingredients, a global producer that markets high-quality whey and milk ingredients, entered the pharmaceutical-grade lactose market by launching a new brand, Lactalis Ingredients Pharma. The new range of Lactalpha includes Lactalpha 50, Lactalpha 100 and Lactalpha 150., In July 2022, DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, expanded its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale 400. The new product is a milled, anhydrous lactose grade..

GlobalData estimates sales of HF therapeutics to be approximately $3.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The HF market will grow at a strong CAGR of 13.5% over the forecast period, reaching sales of $11.5B by 2025. The 7MM chronic HF market size in 2015 was $3.1B, and is expected to increase to $10.1B by 2025 at a CAGR of 12.7%. The US was the largest market for chronic HF therapies, contributing 61.2% of total sales in the base year. GlobalData expects uptake of Novartis' Entresto to be the strongest driver of the chronic HF and total HF markets in the 7MM, reaching peak sales of $5.9B in 2022. The acute HF market is expected to increase from just $188.1M in 2015 to $1.5B in 2025, at a CAGR of 23.0%. Japan dominated the acute HF market in the base year, 2015, accounting for 86.0% of market share. However, with the launch of several acute HF add-on therapies in the forecast period, the US will take over as the acute HF market leader, contributing 68.7% of sales to the acute HF market by 2025. Read More

According to cognitive market research, the global pharmaceutical contract sales outsourcing market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

Pharmaceutical contract sales outsourcing (CSO) is a business model where pharmaceutical companies outsource their sales and marketing operations to third-party companies, also known as contract sales organizations.
In 2024, North America dominated the market, accounting significant share of about xx%. North America is the largest market for Pharmaceutical Contract Sales Outsourcing (CSO) globally.
Over the course of the forecast period, the Asia Pacific region is anticipated to increase at the fastest rate. The need for CSO operations in the region is rising as a result of the large number of pharmaceutical and biopharmaceutical businesses in the area.
Prominent pharmaceutical corporations in the Middle East and Africa are utilizing venture capital to oversee their financial holdings by purchasing shares in start-ups and small-to-medium-sized CMOs that have significant growth prospects.
More biopharma companies in Europe are turning to contract sales organizations to carry out promotional activities, which is why the market in this region is growing. 

Market Dynamics of the Pharmaceutical Contract Sales Outsourcing Market

Key Drivers of the Pharmaceutical Contract Sales Outsourcing Market

Increasing pressure on pharmaceutical companies to reduce costs and improve efficiency propelling the market growth for the pharmaceutical contract sales outsourcing market

The increasing demand on pharmaceutical businesses to increase efficiency and save costs is one of the main factors propelling the growth of the pharmaceutical contract sales outsourcing (CSO) industry. Pharmaceutical businesses can cut costs associated with keeping a specialized sales crew, including salary, benefits, and training fees, by outsourcing their sales activities to independent CSO providers. Furthermore, pharmaceutical businesses may enhance their sales and market share with the assistance of CSO providers, who give specialized sales experience and support. Leading pharmaceutical corporations throughout the world are leveraging venture capital to manage their financial portfolio by investing in early-stage and small-to-medium-sized CMOs that have significant room for expansion. • For instance, Novartis Venture Fund is a part of Swiss multinational Novartis. It manages more than $750 million in committed capital and has more than 40 portfolio companies across North America and Europe. These companies include in vivo cell reprogramming company Capstan Therapeutics, which launched in 2022. (Source:https://www.labiotech.eu/best-biotech/pharma-biotech-venture-capital-arms/ )

Cost control by emerging pharmaceutical companies expands the market growth 

For several years, up-and-coming specialist pharmaceutical companies have been seeking partnerships with well-established pharmaceutical behemoths to introduce their products. Big pharma companies want to work together because they need drugs that can enter their pipelines quickly and affordably. Some agreements range from selling all commercialization rights to licensing goods. Young pharmaceutical companies may build flexibility into their sales strategy right from the beginning by collaborating with a CSO. With the assistance of an experienced CSO partner, emerging businesses can quickly put together an agile, scalable, and responsive team to meet customer demands. This ensures that key market segments are serviced by the right sales personnel and that scaling up or down as the market demands doesn't negatively impact internal operations. • For instance, In July 2021, ICON plc a global provider of outsourced drug and device development and commercialization services to the pharmaceutical, biotechnology, medical device, and government and public health firms acquired PRA Health Sciences, Inc. The merger enhances the consulting, clinical, and commercial services portfolio, geographic presence, therapeutic capabilities, and data-powered healthcare technology of the ICON, which aims to provide internationally scaled expertise and solutions. (Source:https://www.iconplc.com/news-events/press-releases/icon-to-acquire-pra-health-sciences )

Restraints...

The size of the Pharmaceutical Grade Lactose Market was valued at USD 1.20 Billion in 2023 and is projected to reach USD 1.63 Billion by 2032, with an expected CAGR of 4.40% during the forecast period. Pharmaceutical grade lactose refers to the lactose used in the pharmaceutical industry as an excipient in the formulations of tablets and capsules. It is a pure form of lactose of high quality that has been set against very strict standards of quality so that it is safe for consumption by humans. Some of the key characteristics are high purity, low moisture content, and a fine particle size, all important for the maintenance of drug formulation consistency and stability. Applications of pharmaceutical grade lactose are found in all oral solid dosage forms such as tablets, capsules, and powders and are used for inhalers and vaccines. It is used as a binder, filler, and carrier for APIs. The production process is conducted in advanced purification and milling processes to meet the high standards the industry demands. Lactose has an advantage in the market due to growing demand for oral drug delivery systems because it provides low-cost, efficient, and safe options for drug formulation. The main driver of the market is the increasing global pharmaceutical industry. This is so because of the growing cases of chronic diseases and the demand for inexpensive yet safe formulations of drugs. The need for high-quality excipients will continue to rise, and hence, the market is expected to expand. Recent developments include: July 2022: DFE Pharma, a leader in pharma- and nutraceutical excipient solutions, announces the expansion of its dry powder inhalation (DPI) portfolio with the launch of Lactohale 400. Adding Lactohale 400 further enhances the completeness of DFE Pharma's portfolio of inhalation grade lactose., July 2022: Danone launched the first ever Dairy and Plants Blend baby formula in response to parents' desire for vegetarian and flexitarian options for their babies. Plant-based consumption is growing substantially, with over one-third [37%] of EU consumers choosing a vegan, vegetarian or flexitarian diet, and almost 70% [69%] of parents now preferring their children to eat more plant-based foods. Until now, there have been rare options for parents if they choose to move on from breastmilk and want to create healthier, more plant-based food choices and good for the planet.. Notable trends are: Increasing demand for food and infant-grade lactose is driving market growth..

According to the Cognitive Market Research Report, the Clinical Trial Packaging Market size in 2023 was XX Million and is projected to have a compounded annual growth rate of XX% from 2024 to 2031. The drivers of this industry are the increasing number of clinical trials being carried out globally and government initiatives, growing clinical trial spending, and advances in technology. With XX million of the market revenue in 2023 and a market share of almost XX%, North America emerged as the largest market for clinical trial packaging globally. The reason for this is the presence of renowned pharmaceutical markets and top research laboratories. Throughout the analysis period, there has been a comparable increase in mergers and acquisitions in the clinical trials industry. To expand their service offerings and serve a wider patient base, several businesses are purchasing development-stage startups.

Market Dynamics of Clinical Trial Packaging Industry

Key Drivers

The increasing number of clinical trials is being carried out globally is significantly favoring market growth

In the process of creating novel medications or medical equipment, clinical trials are crucial. Novel medications, medical equipment, or any other kind of therapy are the subject of these investigations. A scientific basis for advising and treating patients as well as assessing new drugs and equipment is supplied by these investigations. Clinical trials are being done worldwide due to a surge in research and development (R&D) by the pharmaceutical and biotechnology industries. Since the pharmaceutical industry is subject to strict laws, compliance with these standards is crucial to the success of clinical studies. The need for businesses to come up with packaging options that ensure the integrity and safety of experimental pharmaceutical goods is driving the market, as is the need to adhere to global labeling and packaging regulations. Furthermore, pharmaceutical companies rely heavily on clinical trial packaging to help bridge the gap between medication development and market preparedness. The emergence of innovations like smart solutions and cold seal packaging highlights the industry's dedication to efficiency, innovation, and patient safety. Drug development is not the only factor that will determine pharmaceutical success in the future; successful packaging and delivery of these innovations in a manner that satisfies strict requirements and takes into account the intricate requirements of clinical trials is also critical. For instance, Leading the way in clinical trial supply globally, BAP Pharma specializes in comparator procurement, clinical secondary packaging & labeling, and medication access. The company aims to provide customers with outstanding value and the best possible service.(Source:https://bappharma.com/company/about-us/) Therefore, clinical trial packaging plays a major role in pharmaceutical firms' efforts to close the gap between drug development and launch readiness.

The market for clinical trial packaging is expected to rise as a result of government initiatives, growing clinical trial spending, and advances in technology.

The advent of innovative packaging technologies, such as temperature-controlled solutions and smart packaging, is driving market expansion. By monitoring and maintaining the conditions of the experimental medications during storage and transportation, these advancements raise the standard of clinical trial packaging generally. The market is growing because of the pharmaceutical industry's growing use of contract manufacturing, as well as the growing need and government funding for the creation of novel treatments. The investigators also noted that the emergence of novel ideas in pharmaceutical packaging, such as child-resistant packs, blow-fill seal vials, two-in-one pre-filled vial designs, pre-filled syringes, snap-off ampoules, and pre-filled syringes, contributed to the market's expansion during this time. Furthermore, the government is focussing on environment-friendly packaging and making efforts on sustainable packaging practices. In addition, a growing customer preference for sustainable packaging is expected to remain one of the primary factors likely to influence the development of the global clinical trial packaging market over the projected period, even though several market players are leaning toward adoptin...

Keytruda is projected to stay the top-ranked drug worldwide based on sales in 2025, with some 31 billion U.S. dollars. This statistic displays the expected top drugs in 2025 based on sales projections as of December 2024. It has to be mentioned that Novo Nordisk's brands Ozempic and Wegovy are, in fact, the same drug (generic name semaglutide), where only dosage and dose form define if it is used for diabetes or weight loss. It is very similar in the case of Eli Lilly's Mounjaro and Zepbound which are basically one and the same drug (generic name tirzepatide). Oncology's dominance in pharmaceutical revenues Cancer treatments are becoming increasingly crucial in the pharmaceutical landscape. Keytruda's projected sales for 2025 underscore this trend, while the drug's revenue increased by more than four billion dollars between 2023 and 2024. This growth is part of a larger pattern in global oncology spending, which exceeded 250 billion U.S. dollars globally in 2024, almost doubling from five years earlier. The substantial investment in cancer treatments is likely to continue, with major pharmaceutical companies like Johnson & Johnson, AstraZeneca, and Merck expected to be the oncology market leaders by 2030. Market dynamics and company performance Merck & Co. has seen its overall revenue increase to 64 billion in 2024, driven largely by its oncology franchise. The company's commitment to innovation is evident in its record-high R&D spending in 2023. This focus on research and development is crucial for maintaining competitiveness in the industry, as demonstrated by the changing rankings of top-selling drugs. For instance, AbbVie's Humira, once a blockbuster, dropped out of the top 10 best-selling drugs in 2024 due to patent expiration, highlighting the constant need for pharmaceutical companies to innovate and develop new products to maintain their market position.

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Read More

The size of the Automated Drug Kiosk Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of XXX% during the forecast period. The Automated Drug Kiosk Market refers to the industry segment focused on self-service kiosks that dispense pharmaceutical products, including over-the-counter medications and prescriptions. These kiosks are equipped with technology to automate the dispensing process, allowing customers to retrieve medications without the need for direct interaction with a pharmacist. The market is driven by factors such as increased demand for convenient healthcare solutions, rising adoption of digital health technologies, and the need for more efficient medication distribution in settings like pharmacies, hospitals, and clinics. Automated drug kiosks enhance patient access to medications, reduce waiting times, and improve overall efficiency in drug dispensing. Additionally, they help alleviate the burden on pharmacists and healthcare facilities, making it a growing segment in the healthcare and pharmaceutical industries. The growth of the market is attributed to factors such as the increasing adoption of automated drug dispensing systems in hospitals and pharmacies, the rising prevalence of chronic diseases, and the growing need for medication adherence. Recent developments include: In April 2024, Dallas-based Kiosk operators acquired Wellmation, a pharmaceutical kiosk company, to strengthen its presence in the pharmaceutical industry., In June 2023, Changi General Hospital (CGH) launched the smart pharmacy automated drugs kiosk in Singapore to strengthen its market presence., In March 2019, OnMed announced the development of an interactive telemedicine kiosk, which includes a robotic mini pharmacy that can dispense pharmaceuticals..

There are two clinical forms of age-related macular degeneration (AMD): dry and wet. Currently there are therapies available only for wet AMD. Drugs in late stages of development target the wet AMD segment and the late stage or atrophic form of dry AMD, called geographic atrophy (GA). The global markets are currently overwhelmingly dominated by anti-VEGFs for wAMD, including Lucentis, Eylea, and Avastin, which together accounted for 99.3% of AMD sales. Visudyne, photodynamic therapy (PDT), is used in a minority of patients usually combined with an anti-VEGF.
The AMD pipeline has two longer-acting anti-VEGF drugs (Novartis/Alcon’s brolucizumab and Allergan’s abicipar pegol) and one add-on therapy (Opthea’s OPT-302) in late-stage clinical development (Phase IIb/III) for wet AMD. Three drugs are in the late pipeline for GA, two complement inhibitors (Apellis’ APL-2 and Ophthotech’s Zimura) and a neuroprotective agent (Allergan’s Brimo DDS), which could launch within the forecast period.
GlobalData estimates the 2016 sales for AMD at approximately $4.9B across the 7MM covered in this report. The AMD market will experience a significant growth during the forecast period at a CAGR of 8.9%, with global sales of $11.5B in 2026. Such rapid growth is due primarily to the introduction of the new therapies for the previously untreatable dry AMD patients with GA, launching wet AMD drugs, and the increasing prevalence of AMD as a result of aging societies.
Key Questions Answered
What are the key drivers of significant growth of the AMD market?
How the sales of the current market leader, Bayer’s Eylea, will be affected by the launch of longer-acting anti-VEGF therapies (brolucizumab and abicipar pegol)?
How would physicians fit OPT-302 add-on therapy into the wet AMD treatment algorithm and what is its pricing and reimbursement prospect?
What are the market potentials of drugs developed for the treatment of GA associated with dry AMD, and would they fulfil the greatest unmet need in this space?
How will key patent expiries of anti-VEGF therapies and the use of Avastin impact sales of current and launching therapies in wet AMD?
Will there be opportunities remaining after the launch of late pipeline drugs in wet AMD and dry AMD? Read More

The Injectable Cytotoxic Drugs Marketsize was valued at USD 18.29 USD billion in 2023 and is projected to reach USD 27.87 USD billion by 2032, exhibiting a CAGR of 6.2 % during the forecast period. Cytotoxic drugs are powerful intravenous solutions used to cause the death of cancerous cells by inhibiting their further growth and division. These drugs are injected directly into the bloodstream through the use of a syringe/needle, thus enhancing quick circulation across all parts of the body. These are agents which include alkylating agents, antimetabolites, anthracyclines, and mitotic inhibitors each having their mode of working. They include highly toxic substances that require precise dosages and careful supervision to prevent side effects such as vomiting, hair loss, and weakened bone marrow. Cytotoxic injectable drugs are essential in treatment strategies for some forms of cancer such as breast, lung, and leukemia to eliminate the malignant cells and enhance the patient’s wellness. Recent developments include: June 2023: The U.S. FDA announced the approval of an injectable cytotoxic drug called the Pemrydi RTU, through the 505(b)(2) new drug application pathway., November 2022: Regeneron Pharmaceuticals, Inc. announced that the U.S. FDA had approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy. The drug would be used as the first line of treatment for adult patients diagnosed with advanced Non-Small Cell Lung Cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations., November 2022: GSK opened a USD 44 million production facility to produce a cytotoxic component for antibody-drug conjugates to treat cancer., August 2022: Accord Healthcare launched a chemotherapy drug for brain tumors and blood cancers., March 2022: KELIX bio announced the acquisition of Vitane Pharma GmbH, a life-science company based in Germany. This acquisition strengthened KELIX bio’s portfolio of injectable cytotoxic drugs., April 2019: Sun Pharmaceutical Industries Ltd. announced the launch of INFUGEM, the first cytotoxic drug that comes in premixed, ready-to-infuse formulation to treat breast and lung cancers in the U.S.. Key drivers for this market are: High Dependence on Injectable Cytotoxic Drugs for Treatment of Diseases to Propel Market Growth. Potential restraints include: Advent of Alternate Therapies to Treat Cancer Could Restrain Market Growth. Notable trends are: Strategic Collaborations among Industry Players to Emerge as Vital Trend.

The commercial drug procurement market is experiencing robust growth, driven by the increasing demand for pharmaceutical products globally. The market's expansion is fueled by several key factors, including the rising prevalence of chronic diseases, an aging global population necessitating greater healthcare spending, and ongoing advancements in pharmaceutical research and development leading to the introduction of innovative, and often more expensive, therapies. Furthermore, the increasing outsourcing of procurement functions by pharmaceutical companies to specialized providers, seeking efficiency and cost optimization, contributes significantly to market growth. The market is segmented by application (Life Sciences, Clinical Trials, Others), procurement type (Tender, Direct Procurement, Competitive Negotiation, Others), and geography, with North America and Europe currently holding the largest market shares due to established healthcare infrastructure and higher per capita spending on pharmaceuticals. Competitive dynamics are intense, with established players like McKesson and UPS Healthcare alongside specialized procurement firms like Viseven and Bionical Emas vying for market share. The market faces challenges including stringent regulatory landscapes, pricing pressures from payers, and the complexities inherent in managing global supply chains. However, opportunities exist in the adoption of innovative procurement technologies, such as AI-driven platforms, to improve efficiency and transparency across the entire procurement lifecycle. Looking ahead, the commercial drug procurement market is poised for continued expansion. The ongoing development and launch of novel therapies, particularly in areas such as oncology and immunology, will drive demand. Furthermore, the increasing emphasis on value-based healthcare and the adoption of advanced analytics will shape procurement strategies and create opportunities for providers offering data-driven insights. The competitive landscape is likely to remain dynamic, with consolidation among procurement firms and increased strategic partnerships between pharmaceutical companies and their suppliers. Geographic expansion into emerging markets, particularly in Asia Pacific and Latin America, is also expected to contribute significantly to future market growth. The market's continued evolution necessitates a proactive approach to risk management, addressing challenges related to supply chain resilience, regulatory compliance, and intellectual property protection.

The market is segmented into Active Pharmaceutical Ingredient (API) and Manufacturing Finished Dosage Formulation (FDF). API manufacturing accounts for a significant portion of the market, and FDF is projected to grow faster due to the outsourcing trend for high-potency and complex drug formulations. Recent developments include: In March 2022, Acanthus Research Inc., which provides high-end reference standards and organic synthesis services, launched Acanthus Pharma solution, a CMDO solution for pharmaceutical and biotech services., In October 2022, Medipost announced the establishment of a new CDMO company for cell and gene therapy products in the Korean market. Medipost intends to launch such services as a one-stop solution for the development of pharmaceutical and biopharmaceutical goods., In April 2023, The Bridgewest Group, a global private investment firm that deals with life science software and contract development and manufacturing organizations, created a new Sterile injectables CDMO, NovaCina. NovaCina turns the product into a full-scale commercial product.. Notable trends are: Increases in chronic disease treatment are projected to fuel the market growth.

The Analysis of Pharmaceutical Industry in Australia is Segmented by ATC/Therapeutic Class (Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Cardiovascular System, Dermatologicals, Genito Urinary System and Sex Hormones, Systemic Hormonal Preparations, Anti-Infectives for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Antiparasitic Products, Insecticides, and Repellents, Respiratory System, Sensory Organs, and Other Therapeutic Classes), Drug Type (Branded and Generic), and Prescription Type (Prescription Drugs (Rx) and OTC Drugs). The Report Offers the Value (in USD Million) for the Above Segments.